{"ModuleTitle": "Company Description", "CompanyName": "CTI BioPharma Corp.", "Symbol": "CTIC", "Address": "3101 WESTERN AVENUE SUITE 800, SEATTLE, Washington, 98121, United States of America", "Phone": "2062827100", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on the acquisition, development and\r\ncommercialization of novel targeted therapies for blood-related cancers that\r\noffer a unique benefit to patients and their healthcare providers. Our goal is\r\nto build a profitable company by generating income from products we develop and\r\ncommercialize, either alone or with partners. We concentrate our efforts on\r\ntreatments that target blood-related cancers where there is an unmet medical\r\nneed. In particular, we are focused on evaluating pacritinib, our sole product\r\ncandidate currently in active development, for the treatment of adult patients\r\nwith myelofibrosis.\r\n\r\nPacritinib is an investigational oral kinase inhibitor with specificity for\r\nJAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes is a central component in\r\nsignal transduction pathways, which are critical to normal blood cell growth and\r\ndevelopment, as well as inflammatory cytokine expression and immune responses.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f13%2f0000891293-20-000012.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Adam R. Craig", "title": "President, CEO, Chief Medical Officer & Director"}, {"name": "Bruce J. Seeley", "title": "Chief Operating Officer & Executive Vice President"}, {"name": "David H. Kirske", "title": "Chief Financial Officer & Executive Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}